GET A FREE CONSULTATION Call Us at Advocate Law Group: 888-ITS-LEGAL (888-487-5342) Call Now! Offices: Northern California 2330 Marinship Way, Suite 120Post Office Box 835Sausalito, California 94966-0835 Southern California 78-365 Highway 111, Suite 315La Quinta, CA 92253 Xeljanz Linked to Blood Clots in Lungs Xeljanz and Xeljanz XR (tofacitinib) are very costly bio-engineered drugs made by Pfizer that have been prescribed to treat rheumatoid arthritis, psoriatic arthritis and moderate-to-severe ulcerative colitis. When taken for rheumatoid arthritis and ulcerative colitis, Pfizer recommended that it be taken twice a day in 10mg doses. The drugs, which can cost a patient up to $50,000 a year, generated $1.77 billion in sales for Pfizer in 2018. A just released post-marketing trial study found that at that dosage the drug caused a very high incidence of pulmonary embolisms – blood clots that got caught in one of the arteries that go from the heart to the lungs, blocking the normal flow of blood. Such blockages (pulmonary embolisms) often caused serious to fatal problems, including damage to patients’ lungs and harm to multiple organs due to lower oxygen levels in patients’ blood. In some instances patients died because a single clot became so large that it cut off the blood flow, or an artery became clogged by multiple small clots. The FDA issued a Safety Alert on February, 25, 2019, for Xeljanz and Xeljanz XR (tofacitinib) for increased risk of blood clots in the lungs and death with the higher dosage of the drug (10mg/2 times per day) used by Rheumatoid Arthritis patients. Speak to your doctor before considering any changes to your medications....
